Delisted

No longer trades. Fund positions are valued at its last close, $84.95 on Aug 31, 2026. View SEC filing

CRNX

CRINETICS PHARMACEUTICALS IN

CRNX·22663K107·US·Common Stock·Healthcare - Biotechnology-13D/G

CRNX (CRINETICS PHARMACEUTICALS IN) is held by 137 institutional investors as of Q2 2026. Largest holders: FMR LLC ($592.7M), BlackRock, Inc. ($365.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. ($336.4M).

137
Holders
(11 Elite)
$4B
Total Value
58%
Consensus
13F: Insider & Congress: Updated regularly
CRNX

Smart Money Verdict

View all
Loading verdict
Held by 137 funds
11 elite

Who's Trading

Source dates: Price Aug 31, 2026 · Insiders Sep 1, 2026 · Activists Aug 13, 2026 · Congress none

InsiderKIKalofonos IsabelDisp $142KSep 1, 2026
InsiderNWNichols WestonDisp $1.4MSep 1, 2026
InsiderVRVivaldi Coelho RogerioDisp $1.1MSep 1, 2026
Checking access…

Top Holders

Checking access…
Action
Increased
15.8M(+0.5%)$592.7M0.0%+120.65%
32
Increased
9.8M(+15.1%)$365.2M0.0%+77.09%
36
Increased
9M(+7.8%)$336.4M1.6%+90.71%
53
Decreased
7.1M(-12.6%)$266.8M0.0%+124.26%
0
Increased
6.5M(+1.1%)$241.9M1.4%+216.53%
49
Increased
6.2M(+16.0%)$232.5M0.0%+141.80%
35
Increased
4.8M(+4.2%)$180.8M0.0%+133.61%
32
Increased
4.7M(+1.5%)$177.6M0.0%+133.79%
31
First report
4.6M$170.5M0.1%+127.02%
0
Increased
2.7M(+9.9%)$102.1M0.0%+152.93%
33
Increased
2.7M(+11.9%)$100.6M0.0%+193.81%
34
Unchanged
2.4M$88M0.4%+105.32%
0
New
2.3M$85.1M0.2%+127.02%
49
Increased
2.1M(+10.1%)$77.6M0.1%+102.72%
33
Decreased
1.7M(-2.2%)$62.8M0.1%+141.96%
0
Increased
1.4M(+3.0%)$50.6M0.0%+102.40%
30
Increased
1.3M(+45.5%)$50.1M0.0%+118.19%
40
Increased
1.3M(+86.2%)$49.9M0.0%+137.85%
46
Increased
1.3M(+49.1%)$47.5M0.0%+123.90%
40
Increased
1.3M(+19.9%)$47.2M0.0%+105.11%
35

Showing 1-20 of 150

1 / 8
CRNXCRNXCRINETICS PHARMACEUTICALS IN

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used